Huangjin Erbai Powder Veterinary Grade API is supplied under manufacturer model traceability code HJE-2B-Vet API and is intended exclusively as an unsterilized multi-herb powder intermediate for further manufacture of veterinary dosage forms in tablets, injections, capsules, powders, granules, premix, and solutions. The code links the immediate packaging label to the certificate of analysis and the supplier drug master file; no harmonized public pharmacopoeial monograph is assigned to this specific multi-component powder, so release status is controlled by the DMF and current batch documentation. Production-scale lots are dried to a loss on drying of not more than 5.0% w/w, rotor-milled through a 2.5 mm screen, passed through a pin mill, and sieved through an 80 mesh vibratory screen before blending. The material is not dispensed as a ready-to-use veterinary product; it is an API intermediate that requires formulation and dosage-form-specific processing.

Pharmacopoeial Release Specifications and Supplier DMF Traceability

Release control uses a hybrid specification in which pharmacopoeial test methods are applied to botanical powder parameters; the DMF-listed limits are representative and must be verified against the current certificate of analysis. Table 1 lists the parameters commonly reported for batch release.

Published public data for this specific multi-component powder is limited; therefore the above values should not be treated as a universal specification. Each incoming batch must be compared with the supplier certificate of analysis and, where necessary, re-tested against the approved internal specification before use in GMP manufacture. The loss on drying determination is run at 105°C for 2 h, and total ash is determined after ignition at 600°C. Particle size D90 is measured by laser diffraction using a wet dispersion unit; purified water without surfactant is used unless validation demonstrates insufficient particle wetting. The powder should be protected from light during sampling because the botanical fraction can darken under prolonged exposure.

What Limits Direct Compression for This Multi-Herb Powder?

For direct compression assessment, the bulk powder typically exhibits a Hausner ratio above 1.35 and a compressibility index above 30%, which places it outside the range considered free-flowing for high-speed tableting. On a rotary tablet press with 10.0 mm round flat-faced punches and a precompression force of 8–12 kN, trial batches at target weight 250 mg show weight variation above 3.0% RSD unless granulation is performed. The fibrous and hygroscopic fractions retained after milling adhere to punch faces at residual moisture above 4.5% w/w and become more cohesive when ambient relative humidity exceeds 60%. Consequently, unmodified direct compression is not predicted to meet content uniformity requirements below 5.0% RSD without granulation.

Wet granulation in a high-shear mixer at impeller speed 150–300 rpm and chopper speed 1,500–2,500 rpm is the conventional solid oral route. A binder solution of pregelatinised starch at 5.0% w/w in water is added until a torque plateau is maintained for at least 30 s. The wet mass is dried in a fluid-bed dryer with inlet air temperature 60–70°C until loss on drying falls below 3.0% w/w. Dried granules are screened through a 1.0 mm sieve and blended with disintegrant and lubricant. Tablet hardness is maintained at 40–80 N; compression force above 15 kN increases disintegration time beyond 30 min in media simulating gastric fluid. These parameters are pilot-scale operating ranges rather than regulatory specification limits.

The powder is not compatible with strong oxidising agents, and compatibility with cationic polymers or amine-based film-coating systems should be tested before scale-up because tannin-like constituents can bind to amine groups and form insoluble complexes. Lubricant addition at 0.5% w/w magnesium stearate is typical, but over-lubrication above 2.0% w/w delays disintegration and weakens tablet tensile strength. Crospovidone or croscarmellose sodium at 2.0% w/w is used to offset the hydrophobic effect of the botanical fraction.

When Injectable Dosage Forms Require Endotoxin Control Beyond Powder Release Limits

In injectable processing, the unsterilised powder cannot rely only on the powder release specification because parenteral grade requires bacterial endotoxin control and particulate control independent of nonsterile oral limits. Pilot trials reconstitute the powder in Water for Injections at 25°C under high-shear mixing for 15 min, producing a dark suspension containing a soluble fraction and a colloidal residue. The stream is clarified through a 0.45 µm PVDF membrane and then sterile-filtered through a 0.22 µm PES membrane. Flux decline of 40–60% is observed after approximately 100 L/m² throughput because polysaccharide and proteinaceous fouling reduces the effective membrane area; depth filtration before the 0.22 µm membrane reduces the decline. Terminal sterilisation at 121°C for 15 min is feasible only if the pH is maintained below 7.0; pH values above 7.4 produce visible precipitates in the cooled solution. Phosphate-buffered vehicles are not recommended because calcium and magnesium in the ash fraction can form insoluble phosphate precipitates.

When the solution is prepared for syringeability, osmolality should be adjusted with glycerol or mannitol rather than saline. A 10 g/L reconstitution can raise osmolality by 20–40 mOsm/kg beyond the soluble fraction alone, and the addition of sodium chloride to reach 290 mOsm/kg can trigger precipitation in the presence of residual phosphate species. Unbuffered solution pH shifts by 0.3–0.6 pH units over 24 h at 2–8°C; buffer selection is therefore required before the formulation is scaled. Pre-drying of the powder at 40–50°C for 2 h before reconstitution reduces free moisture and improves filtration performance in high-humidity production sites. Filtration pressures should be controlled below 0.15 MPa differential across the sterilising membrane to avoid particle shedding from the colloidal load.

Segregation Control During Low-Dose Premix and Powder Handling

When the active fraction in a premix is below 5.0% w/w, one-step blending of HJE-2B-Vet API with a free-flowing carrier in a 500 L ribbon blender produces assay relative standard deviation above 8.0%. Stepwise geometric dilution in three stages reduces the RSD to below 5.0%. The powder adheres to the blender wall when ambient relative humidity exceeds 65%; this wall loss can shift the assay by 2–4% if not recovered. Segregation is aggravated by the difference in bulk density between the API and carrier. After the first blending pass, the premix should be discharged through a 0.8 mm sieve and reblended for at least 10 min. For premix batches targeting 1.0% w/w or lower, vibratory transfer into drums should be avoided; a screw conveyor or drop chute with baffles preserves the blend. Sampling is performed according to ISO 6497:2002.

The ribbon blender should be filled to approximately 60% of working capacity and operated at 20 rpm; higher speeds increase dust generation and may reduce the uniformity of the low-dose botanical fraction. If an intensifier bar is used, it should be operated only for the first 5 min after the final addition because extended intensifier action can shred fibrous particles and increase the fine fraction below 0.15 mm. The finished premix should be packed in sealed containers with desiccant when storage relative humidity cannot be maintained below 60%.

Storage Is Not Passive for a Hygroscopic Botanical Powder

Under uncontrolled warehouse humidity above 65%, the powder increases in moisture within 24 h, and the resulting surface water reduces flow and increases adhesion to stainless steel contact surfaces. Storage containers should be sealed HDPE drums with low-density polyethylene liners, protected from light, and maintained below 25°C. Desiccant should be added when the residual water specification below 5.0% w/w must be preserved for parenteral or capsule processing. Open-tank storage is not acceptable because the powder can absorb moisture from processing room air and shift the loss on drying by 0.5–1.5% w/w within a single shift at 70% RH.

Equipment cleaning after contact with this powder is not fully achieved with ambient water alone. Pilot-scale cleaning runs show that residual resinous botanical deposits remain on stainless steel after cold water rinse; hot water at 55°C followed by 1.0% w/w sodium hydroxide solution and a final 0.5% w/w citric acid rinse improves removal. Cleaning validation should include visual inspection and swab testing for total organic carbon rather than relying solely on visual absence of colour. The powder should be segregated from strong acids, strong bases, oxidisers, and open flame because the fine organic fraction can support dust combustion. Local exhaust ventilation is required during sieving and transfer operations.

Compared with single-entity synthetic veterinary APIs, the multi-herb powder differs in composition, assay strategy, flow, and sterilization constraints. Published data for the exact comparative configuration is limited; the profiles in Table 2 are based on general processing behaviour and should be confirmed against the supplier dossier.

For granule and oral powder processing, a top-spray fluid-bed granulator is used when dissolution rate in the finished dosage form is critical. Operating variables include inlet air temperature 55–65°C, spray rate 20–40 g/min per 1.0 kg batch, and atomising air pressure 1.0–1.5 bar. The granulation endpoint is monitored by product temperature and outlet air humidity; overdrying below 1.5% w/w moisture increases friability and dust generation. Retained granules should fall between 0.2 mm and 0.8 mm, and fines below 0.15 mm are recycled only once to avoid excessive fines accumulation. Flow through a 10.0 mm orifice is determined according to USP <1174>; a flow rate of at least 10 g/s is targeted for high-speed capsule machines. For hard capsule filling, size 0 or size 1 capsules are filled after pre-drying at 40–50°C for 2 h because relative humidity above 60% increases powder adhesion to the dosing disk and hopper walls. The granule size fraction between 0.25 mm and 0.85 mm is preferred; finer particles below 0.15 mm segregate to the bottom of the hopper and produce weight variation exceeding 2.5% RSD. When the powder is reconstituted for oral solutions, sedimentation of coarse fibres requires continuous stirring; a concentrated stock solution at 10–20 g/L is prepared and protected from light during holding. The use of preservatives in oral vehicles should be confirmed for antimicrobial effectiveness per Ph. Eur. 5.1.3 or USP <51> before batch release.